Completed


  • Successfully sourced $3.5M Series A funding for a preclinical IVD Device startup with products in Cardiovascular and Oncology space.  Effort included drafting non-confidential "Teaser", Private Placement Memorandum, and a scientific white-paper.  Along with our partners, we and our conducted investor identification, communications, and managed the process through the collection of funds.  
  • Leveraged Asia network to identify local partners in Greater China for a client seeking entry to that market with a portfolio of branded generics across multiple TA's.  Potential in-licensing partners are companies based in China as well as western firms who are seeking assets to compliment their portfolios within China.    


Ongoing


  • Placing early-stage pain asset developed in APAC with western firm having synergistic offerings in area of secondary care 
  • Seeking certain nebulizer formulations and synergistic products in respiratory space immediately available for license in greater China
  • Placing branded generics with a leading MNC expanding their offerings in Greater China
  • Assisting Beijing-based firm with rapid expansion of portfolio with solid-dose generics and branded generics across multiple TA's
  • Seeking strategic partners who can maximize the commercial potential of three respiratory NCE's aimed primarily at asthma and related indications
  • Seeking strategic partners able to maximize NCS assets in neurology space



Valbase Advisors LLC